Cellular Biomedicine Group (CBMG) Misses Q3 EPS by 1c

Cellular Biomedicine Group (NASDAQ: CBMG) reported Q3 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43).

• Cash Position: Cash and cash equivalents as of September 30, 2015 were $20.1 million compared to $14.8 million as of December 31, 2014
• Net Cash Used in Operating Activities: Net cash used in operating activities for the third quarter of 2015 was $2.9 million, compared to $3.4 million for the same period in 2014

For earnings history and earnings-related data on Cellular Biomedicine Group (CBMG) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform